Rigel Pharmaceuticals, Inc

(NASDAQ:RIGL)

Latest On Rigel Pharmaceuticals, Inc (RIGL):

Date/Time Type Description Signal Details
2023-05-26 15:54 ESTNewsRigel Pharmaceuticals Shows Promise With Q1 Earnings: Tavalisse And Rezlidhia Drive GrowthN/A
2023-05-03 02:14 ESTNewsRigel Pharmaceuticals GAAP EPS of -$0.08 beats by $0.02, revenue of $26.07M beats by $2MN/A
2023-05-03 02:13 ESTNewsRigel Pharmaceuticals, Inc. 2023 Q1 - Results - Earnings Call PresentationN/A
2023-05-03 02:13 ESTNewsRigel Pharmaceuticals, Inc. (RIGL) Q1 2023 Earnings Call TranscriptN/A
2023-05-02 01:42 ESTNewsRigel Pharmaceuticals Q1 2023 Earnings PreviewN/A
2023-04-27 09:21 ESTNewsRigel Pharmaceuticals Q1 Preview: A 2-Drug Company Pushing For ProfitabilityN/A
2023-04-04 02:31 ESTNewsRigel Pharma begun at neutral at Piper Sandler on value creation potentialN/A
2023-03-09 06:02 ESTNewsRigel Pharmaceuticals' Challenges Continue To Outweigh Potential UpsideN/A
2023-03-08 00:02 ESTNewsRigel Pharma, with beats on quarterly top and bottom lines, surges 19%N/A
2023-03-08 00:02 ESTNewsRigel Pharmaceuticals GAAP EPS of $0.34 beats by $0.80, revenue of $120.24M beats by $27.04MN/A
2023-03-08 00:02 ESTNewsRigel Pharmaceuticals, Inc. 2022 Q4 - Results - Earnings Call PresentationN/A
2023-03-08 00:02 ESTNewsRigel Pharmaceuticals, Inc. (RIGL) Q4 2022 Earnings Call TranscriptN/A
2023-03-06 18:38 ESTNewsRigel Pharmaceuticals Q4 2022 Earnings PreviewN/A
2023-01-28 01:25 ESTNewsRigel Pharmaceuticals (RIGL) Investor Presentation - SlideshowN/A
2023-01-09 20:04 ESTNewsRigel Pharma rises as preliminary Q4 revenue above estimatesN/A
2022-12-31 03:48 ESTNewsRigel Pharmaceuticals: A Strong Finish To 2022 And A Potentially Transformative 2023N/A
2022-12-22 20:32 ESTNewsRigel launches leukemia therapy in U.S.N/A
2022-12-15 15:09 ESTNewsRigel extends gains as dosing starts in early-stage trial for blood cancer therapyN/A
2022-12-03 04:05 ESTNewsRigel upgraded at Citi on bullish outlook for new leukemia drugN/A
2022-12-02 10:34 ESTNewsRigel stock soars 40% on FDA approval of blood cancer drug RezlidhiaN/A
2022-11-04 07:46 ESTNewsRigel Pharmaceuticals GAAP EPS of -$0.11 beats by $0.03, revenue of $22.4M misses by $0.21MN/A
2022-11-04 07:46 ESTNewsRigel Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call PresentationN/A
2022-11-04 07:46 ESTNewsRigel Pharmaceuticals, Inc. (RIGL) Q3 2022 Earnings Call TranscriptN/A
2022-11-02 22:35 ESTNewsRigel Pharma gains as analysts play down setback for COVID-19 therapyN/A
2022-10-31 23:15 ESTNewsRigel Pharmaceuticals Provides An Opportunity For Investors Or An AcquirerN/A
2022-10-11 06:01 ESTNewsRigel cutting 16% of workforce after declining to file sNDA for fostamatinibN/A
2022-08-18 23:47 ESTNewsRigel Pharma adds ~7% to reach over two month highN/A
2022-08-04 01:22 ESTNewsRigel rises 17% on strong Q2 resultN/A
2022-08-03 10:19 ESTNewsRigel Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call PresentationN/A
2022-08-03 10:19 ESTNewsRigel Pharmaceuticals, Inc. (RIGL) CEO Raul Rodriguez on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-02 20:22 ESTNewsRigel Pharmaceuticals GAAP EPS of -$0.08 beats by $0.04, revenue of $29.82M beats by $6.17MN/A
2022-08-02 05:27 ESTNewsRigel Pharmaceuticals Q2 2022 Earnings PreviewN/A
2022-06-10 02:16 ESTNewsRigel Pharma downgraded at several street firms following anemia study failureN/A
2022-06-09 00:09 ESTNewsRigel stock crashes 48% as fostamatinib fails phase 3 anemia studyN/A
2022-06-09 00:08 ESTNewsRigel cut to Neutral at Cantor Fitzgerald after trial miss wipes out half of stock valueN/A
2022-05-31 10:56 ESTNewsRigel Pharmaceuticals: A Status CheckN/A
2022-05-04 11:44 ESTNewsRigel Pharmaceuticals, Inc.'s (RIGL) CEO Raul Rodriguez on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-03 19:55 ESTNewsRigel Pharmaceuticals GAAP EPS of -$0.16 misses by $0.02, revenue of $16.74M misses by $0.8MN/A
2022-05-03 19:54 ESTNewsRigel Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call PresentationN/A
2022-05-03 01:40 ESTNewsRigel Pharmaceuticals Q1 2022 Earnings PreviewN/A
2022-04-08 20:19 ESTNewsRigel Pharmaceuticals grants stock options to employeesN/A
2022-03-22 02:13 ESTNewsRigel Pharmaceuticals: Why The Stock Is On A RunN/A
2022-03-02 05:58 ESTNewsRigel Pharmaceuticals GAAP EPS of -$0.13 in-line, revenue of $20.41M misses by $0.79MN/A
2022-03-02 05:58 ESTNewsRigel Pharmaceuticals, Inc. (RIGL) CEO Raul Rodriguez on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-02 05:58 ESTNewsRigel Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call PresentationN/A
2022-02-28 17:57 ESTNewsRigel Pharmaceuticals Q4 2021 Earnings PreviewN/A
2022-02-01 13:56 ESTNewsRigel Pharmaceuticals: A Biopharma With A Free Shot On Goal In COVID-19, With A Pipeline As A Safety NetN/A
2022-01-11 00:53 ESTNewsRigel down as it expects slight decrease in products sales in Q4 compared to prior yearN/A
2021-12-22 03:23 ESTNewsRigel Pharma says its trial for bleeding disorder therapy met main goal in JapanN/A
2021-11-30 10:44 ESTNewsRigel Pharmaceuticals: New Omicron Variant Keeps Tavalisse Treatment Prospects AliveN/A

About Rigel Pharmaceuticals, Inc (RIGL):

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase II clinical trial for the treatment of hospitalized COVID-19 patients; and phase II clinical trial for the treatment of COVID-19. In addition, the company is developing R835, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

See Advanced Chart

General

  • Name Rigel Pharmaceuticals, Inc
  • Symbol RIGL
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 169
  • Last Split Factor1:9
  • Last Split Date2003-06-25
  • Fiscal Year EndDecember
  • IPO Date2000-11-29
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.rigel.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 6.34
  • Price/Book (Most Recent Quarter) 20.39
  • Enterprise Value Revenue 6.22
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.02
  • Next Year EPS Estimate -$0.20
  • Next Quarter EPS Estimate -$0.03
  • Profit Margin -27%
  • Operating Margin -27%
  • Return on Assets -14%
  • Return on Equity -68%
  • Revenue 108.62 million
  • Earnings Per Share -$0.35
  • Revenue Per Share $0.64
  • Gross Profit 47.63 million
  • Quarterly Earnings Growth 19.8%
View More

Highlights

  • Market Capitalization 689.52 million
  • EBITDA -60896000
  • PE Ratio -16.62
  • PEG Ratio -0.1
  • Analyst Target Price $8.5
  • Book Value Per Share $0.20
View More

Share Statistics

  • Shares Outstanding 170.04 million
  • Shares Float 169.52 million
  • % Held by Insiders 31%
  • % Held by Institutions 85.26%
  • Shares Short 16.81 million
  • Shares Short Prior Month 19.36 million
  • Short Ratio 3.15
  • Short % of Float 11%
  • Short % of Shares Outstanding 10%
View More

Technicals

  • Beta 1.45
  • 52 Week High $5.5
  • 52 Week Low $1.26
  • 50 Day Moving Average 4.2
  • 200 Day Moving Average 3.23
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Rigel Pharmaceuticals, Inc (RIGL) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Rigel Pharmaceuticals, Inc (RIGL) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-02$18.45 million-$0.11-$0.113.51%
2020-09-302020-11-05$18.39 million-$0.08-$0.1234.05%
2020-06-302020-08-04$16.02 million-$0.10-$0.1426.09%
2020-03-312020-05-05$55.76 million$0.13$0.13-1.59%
2019-12-312020-02-27$15.4 million-$0.10-$0.1217.56%
2019-09-302019-11-05$20.86 million-$0.07-$0.1032.69%
2019-06-302019-08-06$10.41 million-$0.12-$0.1412.22%
2019-03-312019-05-07$12.62 million-$0.11-$0.1315.38%
2018-12-312019-02-28$37.86 million$0.02$0.03-41.35%
2018-09-302018-11-06$4.87 million-$0.14-$0.157.83%
2018-06-302018-08-08$1.79 million-$0.16-$0.16-0.19%
2018-03-312018-05-01$N/A-$0.17-$0.183.41%
2017-12-312018-03-06$3.58 million-$0.18-$0.13-35.03%
2017-09-302017-11-07$900000-$0.14-$0.158.32%
2017-06-302017-08-01$-3584000-$0.16-$0.14-12.76%
2017-03-312017-05-02$3.58 million-$0.13-$0.12-5.18%
2016-12-312017-03-07$3 million-$0.16-$0.175.33%
2016-09-302016-11-01$3.76 million-$0.24-$0.23-3.99%
2016-06-302016-08-02$8.59 million-$0.15-$0.2026.33%
2016-03-312016-05-03$5.03 million-$0.19-$0.219.18%
2015-12-312016-03-08$8.54 million-$0.14-$0.14-3.47%
2015-09-302015-11-03$13 million-$0.08-$0.1752.94%
2015-06-302015-08-04$5.18 million-$0.16-$0.2227.27%
2015-03-312015-05-07$2.18 million-$0.21-$0.18-16.67%
2014-12-312015-03-03$8.25 million-$0.15-$0.2642.31%
2014-09-302014-11-04$N/A-$0.24-$0.2711.11%
2014-06-302014-08-05$N/A-$0.29-$0.25-16%
2014-03-312014-05-07$N/A-$0.25-$0.250%
2013-12-312014-03-04$5.75 million-$0.19-$0.2524%
2013-09-302013-11-05$-1400000-$0.25-$0.2913.79%
2013-06-302013-08-06$1.4 million-$0.26-$0.3013.33%
2013-03-312013-05-07$N/A-$0.29-$0.303.33%
2012-12-312013-03-05$2.25 million-$0.30-$0.326.25%
2012-09-302012-11-06$-1500000-$0.36-$0.372.7%
2012-06-302012-08-07$1.5 million-$0.35-$0.350%
2012-03-312012-05-01$750000-$0.32-$0.31-3.23%
2011-12-312012-03-06$395000-$0.36-$0.28-28.57%
2011-09-302011-11-01$4.36 million-$0.25-$0.3016.67%
2011-06-302011-08-02$395000-$0.37-$0.382.63%
2011-03-312011-05-03$N/A-$0.40-$0.36-11.11%
2010-12-312011-03-01$52.72 million-$0.33-$0.368.33%
2010-09-302010-11-02$72.28 million$0.96$0.6254.84%
2010-06-302010-08-03$49.46 million$0.51$0.478.51%
2010-03-312010-05-04$3.26 million-$0.43$0.11-490.91%
2009-12-312010-03-02$750000-$0.48-$0.45-6.67%
2009-09-302009-11-03$N/A-$0.70-$0.58-20.69%
2009-06-302009-08-04$N/A-$0.81-$0.810%
2009-03-312009-05-05$N/A-$0.82-$0.9917.17%
2008-12-312009-02-24$N/A-$0.91-$0.976.19%
2008-09-302008-11-03$N/A-$1.03-$0.87-18.39%
2008-06-302008-08-05$N/A-$0.93-$0.69-34.78%
2008-03-312008-05-06$N/A-$0.79-$0.62-27.42%
2007-12-312008-02-12$8 million-$0.61-$0.43-41.86%
2007-09-302007-11-06$-1956000-$0.61-$0.57-7.02%
2007-06-302007-08-07$1.96 million-$0.68-$0.63-7.94%
2007-03-312007-05-10$2.64 million-$0.68-$0.67-1.49%
2006-12-312007-02-06$3.13 million-$0.62-$0.643.13%
2006-09-302006-11-07$6.13 million-$0.46-$0.472.13%
2006-06-302006-08-02$14.32 million-$0.09-$0.5683.93%
2006-03-312006-05-02$9.9 million-$0.34-$0.32-6.25%
2005-12-312006-02-07$6.02 million-$0.36-$0.4316.28%
2005-09-302005-11-08$3.28 million-$0.56-$0.618.2%
2005-06-302005-08-03$4.61 million-$0.62-$0.7112.68%
2005-03-312005-05-03$2.62 million-$0.57-$0.48-18.75%
2004-12-312005-02-08$1.1 million-$0.75-$0.69-8.7%
2004-09-302004-11-05$659000-$0.88-$0.71-23.94%
2004-06-302004-08-03$1.49 million-$0.68-$0.748.11%
2004-03-312004-05-04$1.49 million-$0.81-$0.78-3.85%
2003-12-312004-02-03$2.11 million-$0.80-$0.71-12.68%
2003-09-302003-11-05$2.1 million-$0.78
2003-06-302003-08-05$2.35 million-$1.90
2003-03-312003-05-06$4.5 million-$1.53
2002-12-312003-02-05$3.7 million-$1.62-$2.1625%
2002-09-302002-11-04$3.65 million-$1.98-$1.80-10%
2002-06-302002-08-06$4.34 million-$2.07-$1.35-53.33%
2002-03-312002-05-07$4.1 million-$1.71-$1.53-11.76%
2001-12-312002-02-05$4.78 million-$1.44-$1.8421.74%
2001-09-302001-11-07$4.21 million-$1.53-$1.530%
2001-06-302001-08-08$3.12 million-$1.80-$0.99-81.82%
2001-03-312001-05-08$3.19 million-$0.99-$1.4431.25%
2000-12-312001-02-07$3.21 million-$3.24-$2.34-38.46%

Rigel Pharmaceuticals, Inc (RIGL) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Rigel Pharmaceuticals, Inc (RIGL) Chart:

Rigel Pharmaceuticals, Inc (RIGL) News:

Below you will find a list of latest news for Rigel Pharmaceuticals, Inc (RIGL) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Rigel Pharmaceuticals, Inc (RIGL) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-07-17200CALL0 2482.28TRUE00
2026-07-17210CALL0 0111.9TRUE00
2026-07-17220CALL0 0102.18TRUE00
2026-07-17230CALL0 0100.69TRUE00
2026-07-17240CALL0 083.83TRUE00
2026-07-17250CALL0 075.1TRUE00
2026-07-17260CALL0 066.62TRUE00
2026-07-17270CALL0 072.02TRUE00
2026-07-17285.99CALL1 290.6TRUE5.990
2026-07-17290CALL0 2981.24TRUE00
2026-07-17300CALL0 1652.59TRUE00
2026-07-17310CALL0 174.19TRUE00
2026-07-17320CALL0 2069.89TRUE00
2026-07-17332.21CALL5 165.56FALSE2.210
2026-07-17341.8CALL3 967.06FALSE-0.12-0.06
2026-07-17351.7CALL0 1972.44FALSE00
2026-07-17360CALL0 198.14FALSE00
2026-07-17371.66CALL0 6104.62FALSE00
2026-07-17381.21CALL1 278.92FALSE0.360.42
2026-07-17390CALL0 183.34FALSE00
2026-07-17400.34CALL2 462.74FALSE0.340
2026-07-17450.5CALL3 782.37FALSE-0.35-0.41
2026-07-17200PUT0 3247.77FALSE00
2026-07-17210PUT0 0231.22FALSE00
2026-07-17220PUT0 0215.42FALSE00
2026-07-17230PUT0 0200.27FALSE00
2026-07-17240PUT0 0185.68FALSE00
2026-07-17250PUT0 177.36FALSE00
2026-07-17260PUT0 1157.84FALSE00
2026-07-17270PUT0 4144.44FALSE00
2026-07-17280PUT0 6131.28FALSE00
2026-07-17290PUT0 0118.27FALSE00
2026-07-17301.12PUT3 8161.7FALSE1.120
2026-07-17310PUT0 252.44FALSE00
2026-07-17320PUT0 081.65FALSE00
2026-07-17330PUT0 166.87TRUE00
2026-07-17340PUT0 060.26TRUE00
2026-07-17350PUT0 061.36TRUE00
2026-07-17360PUT0 063.73TRUE00
2026-07-17370PUT0 1150.62TRUE00
2026-07-17380PUT0 353.27TRUE00
2026-07-17390PUT0 047.09TRUE00
2026-07-17400PUT0 038.25TRUE00
2026-07-17450PUT0 056.55TRUE00
2026-08-21250CALL0 091.98TRUE00
2026-08-21260CALL0 085.06TRUE00
2026-08-21270CALL0 086.71TRUE00
2026-08-21280CALL0 083.92TRUE00
2026-08-21290CALL0 080.64TRUE00
2026-08-21300CALL0 081.97TRUE00
2026-08-21310CALL0 077.57TRUE00
2026-08-21324.54CALL6 079.34TRUE4.540
2026-08-21330CALL0 081.72FALSE00
2026-08-21340CALL0 076.55FALSE00
2026-08-21350CALL0 074.9FALSE00
2026-08-21360CALL0 074.46FALSE00
2026-08-21370CALL0 075.72FALSE00
2026-08-21380CALL0 076.47FALSE00
2026-08-21390CALL0 081.51FALSE00
2026-08-21401.54CALL2 076.47FALSE1.540
2026-08-21410CALL0 090.76FALSE00
2026-08-21250PUT0 0116.25FALSE00
2026-08-21260PUT0 0107.02FALSE00
2026-08-21270PUT0 098.01FALSE00
2026-08-21280PUT0 089.16FALSE00
2026-08-21290PUT0 082.02FALSE00
2026-08-21300PUT0 073.24FALSE00
2026-08-21310PUT0 068.81FALSE00
2026-08-21320PUT0 070FALSE00
2026-08-21330PUT0 069.41TRUE00
2026-08-21340PUT0 068.09TRUE00
2026-08-21350PUT0 066.97TRUE00
2026-08-21360PUT0 069.73TRUE00
2026-08-21370PUT0 063.43TRUE00
2026-08-21380PUT0 068.78TRUE00
2026-08-21390PUT0 062.71TRUE00
2026-08-21400PUT0 067.24TRUE00
2026-08-21410PUT0 064.87TRUE00
2026-09-18150CALL0 0127.4TRUE00
2026-09-18180CALL0 1105.74TRUE00
2026-09-18190CALL0 099.82TRUE00
2026-09-18200CALL0 1104.26TRUE00
2026-09-18210CALL0 099.5TRUE00
2026-09-18220CALL0 093.32TRUE00
2026-09-18230CALL0 089.92TRUE00
2026-09-18240CALL0 088.71TRUE00
2026-09-18250CALL0 10986.98TRUE00
2026-09-18260CALL0 077.46TRUE00
2026-09-18270CALL0 1778.34TRUE00
2026-09-18280CALL0 781.22TRUE00
2026-09-18290CALL0 1775.3TRUE00
2026-09-18300CALL0 6778.57TRUE00
2026-09-18310CALL0 41477.81TRUE00
2026-09-18320CALL0 071.83TRUE00
2026-09-18330CALL0 971.03FALSE00
2026-09-18340CALL0 2269.75FALSE00
2026-09-18354.26CALL0 1572.18FALSE00
2026-09-18360CALL0 871.87FALSE00
2026-09-18370CALL0 1771.89FALSE00
2026-09-18380CALL0 168.79FALSE00
2026-09-18390CALL0 571.1FALSE00
2026-09-18402.54CALL0 1281.42FALSE00
2026-09-18410CALL0 5478.11FALSE00
2026-09-18420CALL0 2679.27FALSE00
2026-09-18430CALL0 482.27FALSE00
2026-09-18440CALL0 585.52FALSE00
2026-09-18450CALL0 1469.42FALSE00
2026-09-18462.21CALL2 2070.21FALSE2.210
2026-09-18501.9CALL3 4674.2FALSE1.90
2026-09-18551.65CALL1 2080.29FALSE1.650
2026-09-18150.3PUT1 37159.48FALSE0.050.2
2026-09-18180.55PUT1 10119.2FALSE0.10.22
2026-09-18190.65PUT1 6124.85FALSE0.650
2026-09-18200.75PUT1 8120.72FALSE0.750
2026-09-18210.85PUT1 3105.34FALSE0.850
2026-09-18220.95PUT1 580.14FALSE0.950
2026-09-18231.05PUT1 690.36FALSE1.050
2026-09-18240PUT0 0105.35FALSE00
2026-09-18250PUT0 10882.13FALSE00
2026-09-18260PUT0 191.26FALSE00
2026-09-18270PUT0 383.69FALSE00
2026-09-18280PUT0 378.57FALSE00
2026-09-18290PUT0 275.1FALSE00
2026-09-18303.4PUT6 11877.24FALSE3.40
2026-09-18310PUT0 868.92FALSE00
2026-09-18320PUT0 370.39FALSE00
2026-09-18330PUT0 269.71TRUE00
2026-09-18340PUT0 1068.53TRUE00
2026-09-18350PUT0 1371.04TRUE00
2026-09-18360PUT0 068.89TRUE00
2026-09-18370PUT0 068.57TRUE00
2026-09-18380PUT0 170.92TRUE00
2026-09-18390PUT0 067.38TRUE00
2026-09-18400PUT0 1268.16TRUE00
2026-09-18410PUT0 066.91TRUE00
2026-09-18420PUT0 070.46TRUE00
2026-09-18430PUT0 068.48TRUE00
2026-09-18440PUT0 067.87TRUE00
2026-09-18450PUT0 1062.57TRUE00
2026-09-18460PUT0 059.35TRUE00
2026-09-18500PUT0 064.72TRUE00
2026-09-18550PUT0 10TRUE00
2026-12-18150CALL0 1287.72TRUE00
2026-12-18200CALL0 086.12TRUE00
2026-12-18220CALL0 079.5TRUE00
2026-12-18230CALL0 082.07TRUE00
2026-12-18240CALL0 075.97TRUE00
2026-12-18250CALL0 179.14TRUE00
2026-12-18260CALL0 078.74TRUE00
2026-12-18270CALL0 279.37TRUE00
2026-12-18280CALL0 076.39TRUE00
2026-12-18290CALL0 076.42TRUE00
2026-12-18300CALL0 1977.96TRUE00
2026-12-18310CALL0 873.27TRUE00
2026-12-18320CALL0 171.97TRUE00
2026-12-18330CALL0 174.39FALSE00
2026-12-18340CALL0 475.38FALSE00
2026-12-18356.5CALL0 774.48FALSE00
2026-12-18360CALL0 072.3FALSE00
2026-12-18370CALL0 2270.47FALSE00
2026-12-18380CALL0 472.22FALSE00
2026-12-18390CALL0 671.62FALSE00
2026-12-18404.75CALL1 1774.34FALSE4.750
2026-12-18454.31CALL3 3276.25FALSE4.310
2026-12-18150PUT0 7139.99FALSE00
2026-12-18200PUT0 9102.01FALSE00
2026-12-18220PUT0 187.7FALSE00
2026-12-18230PUT0 182.92FALSE00
2026-12-18240PUT0 578.25FALSE00
2026-12-18250PUT0 2076.29FALSE00
2026-12-18260PUT0 079.07FALSE00
2026-12-18270PUT0 075.53FALSE00
2026-12-18280PUT0 074.83FALSE00
2026-12-18290PUT0 072.31FALSE00
2026-12-18304.48PUT5 373.24FALSE4.480
2026-12-18310PUT0 173.23FALSE00
2026-12-18320PUT0 073.23FALSE00
2026-12-18330PUT0 070.16TRUE00
2026-12-18346.73PUT10 072.45TRUE6.730
2026-12-18350PUT0 168.43TRUE00
2026-12-18360PUT0 072.37TRUE00
2026-12-18370PUT0 072.28TRUE00
2026-12-18380PUT0 070.35TRUE00
2026-12-18390PUT0 072.01TRUE00
2026-12-18400PUT0 069.68TRUE00
2026-12-18450PUT0 070.67TRUE00

Latest RIGL Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST100$0.6924
Jun 13, 2022 7:59 PM EST200$0.6924
Jun 13, 2022 7:59 PM EST100$0.6924
Jun 13, 2022 7:59 PM EST500$0.6924
Jun 13, 2022 7:59 PM EST850$0.6921

Rigel Pharmaceuticals, Inc (RIGL) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006136/0001179110-20-006136-index.htm
2019-02-06SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000021545719005836/0000215457-19-005836-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000031506619001306/0000315066-19-001306-index.htm
2020-02-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000031506620001146/0000315066-20-001146-index.htm
2020-02-06SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000083423720006820/0000834237-20-006820-index.htm
2020-07-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000083423720009960/0000834237-20-009960-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000090221919000369/0000902219-19-000369-index.htm
2020-01-27SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000090221920000160/0000902219-20-000160-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000093041319000568/0000930413-19-000568-index.htm
2019-04-09DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1034842/000104746919002080/0001047469-19-002080-index.htm
2020-04-01DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1034842/000104746920001990/0001047469-20-001990-index.htm
2020-05-01DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1034842/000104746920002759/0001047469-20-002759-index.htm
2020-08-04424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1034842/000104746920004389/0001047469-20-004389-index.htm
2018-05-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465918034498/0001104659-18-034498-index.htm
2018-05-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465918037232/0001104659-18-037232-index.htm
2018-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465918050532/0001104659-18-050532-index.htm
2018-08-08S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1034842/000110465918050560/0001104659-18-050560-index.htm
2018-10-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465918060459/0001104659-18-060459-index.htm
2018-10-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465918064285/0001104659-18-064285-index.htm
2018-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465918066323/0001104659-18-066323-index.htm
2019-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919001118/0001104659-19-001118-index.htm
2019-01-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919002845/0001104659-19-002845-index.htm
2019-02-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919005217/0001104659-19-005217-index.htm
2019-02-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919011582/0001104659-19-011582-index.htm
2019-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919017440/0001104659-19-017440-index.htm
2019-04-09DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1034842/000110465919020480/0001104659-19-020480-index.htm
2019-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919027507/0001104659-19-027507-index.htm
2019-05-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919029862/0001104659-19-029862-index.htm
2019-05-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919031798/0001104659-19-031798-index.htm
2019-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919044305/0001104659-19-044305-index.htm
2019-08-07S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1034842/000110465919044376/0001104659-19-044376-index.htm
2019-10-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919052388/0001104659-19-052388-index.htm
2019-10-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919055689/0001104659-19-055689-index.htm
2019-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919060054/0001104659-19-060054-index.htm
2019-11-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919065084/0001104659-19-065084-index.htm
2019-11-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919066635/0001104659-19-066635-index.htm
2019-12-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465919073467/0001104659-19-073467-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920003446/0001104659-20-003446-index.htm
2020-02-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000110465920016449/0001104659-20-016449-index.htm
2020-02-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920026180/0001104659-20-026180-index.htm
2020-04-01DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1034842/000110465920041947/0001104659-20-041947-index.htm
2020-05-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920056879/0001104659-20-056879-index.htm
2020-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920062621/0001104659-20-062621-index.htm
2020-08-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920090262/0001104659-20-090262-index.htm
2020-08-04S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1034842/000110465920090388/0001104659-20-090388-index.htm
2020-10-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920113467/0001104659-20-113467-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1034842/000110465920121776/0001104659-20-121776-index.htm
2018-05-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018006680/0001179110-18-006680-index.htm
2018-05-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018006681/0001179110-18-006681-index.htm
2018-05-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018006682/0001179110-18-006682-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007148/0001179110-18-007148-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007149/0001179110-18-007149-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007150/0001179110-18-007150-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007151/0001179110-18-007151-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007152/0001179110-18-007152-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007153/0001179110-18-007153-index.htm
2018-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018007154/0001179110-18-007154-index.htm
2018-06-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018008174/0001179110-18-008174-index.htm
2018-06-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018008176/0001179110-18-008176-index.htm
2018-07-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018009506/0001179110-18-009506-index.htm
2018-08-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018010636/0001179110-18-010636-index.htm
2018-08-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018010749/0001179110-18-010749-index.htm
2018-08-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018010936/0001179110-18-010936-index.htm
2018-09-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018011179/0001179110-18-011179-index.htm
2018-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018011343/0001179110-18-011343-index.htm
2018-09-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018011567/0001179110-18-011567-index.htm
2018-10-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911018012211/0001179110-18-012211-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000931/0001179110-19-000931-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000932/0001179110-19-000932-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000933/0001179110-19-000933-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000934/0001179110-19-000934-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000935/0001179110-19-000935-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000936/0001179110-19-000936-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000938/0001179110-19-000938-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000939/0001179110-19-000939-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019000940/0001179110-19-000940-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004205/0001179110-19-004205-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004206/0001179110-19-004206-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004207/0001179110-19-004207-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004208/0001179110-19-004208-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004209/0001179110-19-004209-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004210/0001179110-19-004210-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004211/0001179110-19-004211-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004212/0001179110-19-004212-index.htm
2019-04-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004736/0001179110-19-004736-index.htm
2019-04-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019004740/0001179110-19-004740-index.htm
2019-05-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006608/0001179110-19-006608-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006694/0001179110-19-006694-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006698/0001179110-19-006698-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006699/0001179110-19-006699-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006700/0001179110-19-006700-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006701/0001179110-19-006701-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006702/0001179110-19-006702-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019006703/0001179110-19-006703-index.htm
2019-11-143Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011701/0001179110-19-011701-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011937/0001179110-19-011937-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011938/0001179110-19-011938-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011940/0001179110-19-011940-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011942/0001179110-19-011942-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011944/0001179110-19-011944-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011946/0001179110-19-011946-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911019011948/0001179110-19-011948-index.htm
2020-02-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020001348/0001179110-20-001348-index.htm
2020-02-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020001349/0001179110-20-001349-index.htm
2020-02-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020001350/0001179110-20-001350-index.htm
2020-02-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020001351/0001179110-20-001351-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006129/0001179110-20-006129-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006130/0001179110-20-006130-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006131/0001179110-20-006131-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006132/0001179110-20-006132-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006133/0001179110-20-006133-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006134/0001179110-20-006134-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006135/0001179110-20-006135-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020006136/0001179110-20-006136-index.htm
2020-08-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020009204/0001179110-20-009204-index.htm
2020-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1034842/000117911020009207/0001179110-20-009207-index.htm
2019-11-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000131924419000084/0001319244-19-000084-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1034842/000131924420000054/0001319244-20-000054-index.htm
2018-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837018006758/0001558370-18-006758-index.htm
2018-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837018008624/0001558370-18-008624-index.htm
2019-02-2810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1034842/000155837019001310/0001558370-19-001310-index.htm
2019-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837019004244/0001558370-19-004244-index.htm
2019-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837019007232/0001558370-19-007232-index.htm
2019-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837019009974/0001558370-19-009974-index.htm
2020-02-2710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1034842/000155837020001624/0001558370-20-001624-index.htm
2020-05-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837020005179/0001558370-20-005179-index.htm
2020-08-0410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837020009154/0001558370-20-009154-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1034842/000155837020012838/0001558370-20-012838-index.htm
2019-03-20CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1034842/999999999719001548/9999999997-19-001548-index.htm
2020-01-16CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1034842/999999999720000137/9999999997-20-000137-index.htm
2020-01-16CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1034842/999999999720000138/9999999997-20-000138-index.htm
2020-01-16CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1034842/999999999720000139/9999999997-20-000139-index.htm
2020-02-05SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1034842/999999999720000517/9999999997-20-000517-index.htm
2020-02-18SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1034842/999999999720000741/9999999997-20-000741-index.htm
2020-04-24CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1034842/999999999720002114/9999999997-20-002114-index.htm
2020-04-24CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1034842/999999999720002115/9999999997-20-002115-index.htm

Rigel Pharmaceuticals, Inc (RIGL) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Rigel Pharmaceuticals, Inc (RIGL). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 31%
Institutional Ownership: 8526%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-07-02Anne-Marie DuliegeEVP & Chief Medical OfficerSell5,000.002.7913,932.000.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018009506/0001179110-18-009506-index.htm
2018-09-04Anne-Marie DuliegeEVP & Chief Medical OfficerSell16,500.003.5157,860.550.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011179/0001179110-18-011179-index.htm
2018-09-17Anne-Marie DuliegeEVP & Chief Medical OfficerSell115,500.003.50404,250.000.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011567/0001179110-18-011567-index.htm
2018-08-23Eldon C. III MayerEVP & Chief Commercial OfficerBuy100,000.002.82282,320.00115,000.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018010936/0001179110-18-010936-index.htm
2018-09-17Anne-Marie DuliegeEVP & Chief Medical OfficerBuy115,500.002.54293,370.00115,500.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011567/0001179110-18-011567-index.htm
2018-09-04Anne-Marie DuliegeEVP & Chief Medical OfficerBuy16,500.002.5441,910.0016,500.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011179/0001179110-18-011179-index.htm
2018-09-10Eldon C. III MayerEVP & Chief Commercial OfficerBuy50,000.003.28164,210.00165,000.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011343/0001179110-18-011343-index.htm
2018-08-17RAUL R RODRIGUEZCEO, PresidentBuy114,000.002.63300,002.40173,519.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018010749/0001179110-18-010749-index.htm
2018-09-11Eldon C. III MayerEVP & Chief Commercial OfficerBuy50,000.003.23161,340.00215,000.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011343/0001179110-18-011343-index.htm
2018-09-17Anne-Marie DuliegeEVP & Chief Medical OfficerBuy37,500.002.1179,125.0037,500.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018011567/0001179110-18-011567-index.htm
2019-05-22Dean L SchornoEVP &Chief Financial OfficerBuy46,726.002.1399,573.1146,726.00https://www.sec.gov/Archives/edgar/data/1034842/000117911019006608/0001179110-19-006608-index.htm
2019-05-22Dean L SchornoEVP &Chief Financial OfficerBuy3,274.002.136,971.0050,000.00https://www.sec.gov/Archives/edgar/data/1034842/000117911019006608/0001179110-19-006608-index.htm
2018-10-12Nelson CabatuanPrincipal Accounting OfficerSell10,000.003.1231,200.0058.00https://www.sec.gov/Archives/edgar/data/1034842/000117911018012211/0001179110-18-012211-index.htm